NewAmsterdam Pharma (NAMS) Profit After Tax (2023 - 2026)

NewAmsterdam Pharma has reported Profit After Tax for 4 years, with the latest figure at -$49.0 million in Q1 2026.

• Quarterly Profit After Tax fell 23.9% year-over-year to -$49.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$213.4 million (down 13.89% YoY) and the FY2025 annual result came in at -$203.8 million, up 15.64% from the prior year.
• Profit After Tax grew to -$49.0 million in Q1 2026 per NAMS's latest filing, from -$74.9 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$16.6 million in Q3 2024 and troughed at -$93.8 million in Q1 2024.
• A 4-year average of -$51.7 million and a median of -$47.1 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax surged 64.68% in 2024, then tumbled 332.54% in 2025.
• Over 4 years, Profit After Tax stood at -$49.5 million in 2023, then sank by 86.23% to -$92.2 million in 2024, then rose by 18.72% to -$74.9 million in 2025, then soared by 34.58% to -$49.0 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$49.0 million, -$74.9 million, and -$72.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.